Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031367701> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W3031367701 endingPage "e22002" @default.
- W3031367701 startingPage "e22002" @default.
- W3031367701 abstract "e22002 Background: The safety and efficacy of concurrent radiotherapy (SRS) and single agent (anti-PD-1) checkpoint inhibitor have not been established. We report the first results of an interim analysis from a prospective pilot phase II trial of cocurrent anti-PD-1 (pembrolizumab) and SRS for brain metastases Methods: Food and Drug Administration (FDA) and Institutional Review Board (IRB) approval were obtained to conduct a prospective trial with three different radiation dose arms (Arm A: 6 Gray (Gy) in 5 fractions (fx), 9 Gy in 3 fractions, and 18-21 Gy in single fraction) in combination with Pembrolizumab. Patients with not more than 10 brain metastasis who have not received prior brain radiation were eligible. Routine statistical methods were used to estimate control of brain metastases within the irradiated volume (local control, LC), anywhere intra-cranial control (AICC), progression free survival (PFS), and overall survival (OS). RECSIST 1.1 criteria were used to assess. Safety was monitored using NCI CTCAE v 4.0 criteria for toxicity assessment while intracranial and extracranial treatment response was assessed according to RECIST 1.1 criteria. Patients were enrolled from 2017-2020. Results: We report interim analysis from the first 18 patients of planned 36 patients who have completed treatments on each of the three different radiation dose arms (12 patients per arm). All patients received PD1 on day 0, immediately followed by SRS within 2-3 days. At 6 months, the LC (94.0% [CI: 65-99.1]), AICC (70.6% [CI: 43.1-86.65]), PFS (50% [24.5-71]), and OS (77.4% [50.3-90.9]) were higher than expected with either SRS alone or PD1 alone, and appear to be comparable to dual checkpoint, but with much less toxicity. No grade 4 or grade 5 toxicity was noted. The primary endpoint of safety, based on the absence of grade 3 CNS toxicity at 3 months was met with all three radiation dose arms. Overall rate of grade 1-3 toxicity was also within acceptable range. Conclusions: Preliminary prospective results of concurrent SRS and single agent pembrolizumab for brain metastases in melanoma and NSCLC supports this strategy as a safe and promising option compared with dual agent therapy. Clinical trial information: NCT02858869." @default.
- W3031367701 created "2020-06-05" @default.
- W3031367701 creator A5015060656 @default.
- W3031367701 creator A5016808814 @default.
- W3031367701 creator A5036855109 @default.
- W3031367701 creator A5043541884 @default.
- W3031367701 creator A5045125822 @default.
- W3031367701 creator A5056670989 @default.
- W3031367701 creator A5059344570 @default.
- W3031367701 creator A5072862438 @default.
- W3031367701 creator A5076064890 @default.
- W3031367701 creator A5076832426 @default.
- W3031367701 creator A5088178599 @default.
- W3031367701 date "2020-05-20" @default.
- W3031367701 modified "2023-10-03" @default.
- W3031367701 title "Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869)." @default.
- W3031367701 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e22002" @default.
- W3031367701 hasPublicationYear "2020" @default.
- W3031367701 type Work @default.
- W3031367701 sameAs 3031367701 @default.
- W3031367701 citedByCount "3" @default.
- W3031367701 countsByYear W30313677012021 @default.
- W3031367701 countsByYear W30313677012022 @default.
- W3031367701 crossrefType "journal-article" @default.
- W3031367701 hasAuthorship W3031367701A5015060656 @default.
- W3031367701 hasAuthorship W3031367701A5016808814 @default.
- W3031367701 hasAuthorship W3031367701A5036855109 @default.
- W3031367701 hasAuthorship W3031367701A5043541884 @default.
- W3031367701 hasAuthorship W3031367701A5045125822 @default.
- W3031367701 hasAuthorship W3031367701A5056670989 @default.
- W3031367701 hasAuthorship W3031367701A5059344570 @default.
- W3031367701 hasAuthorship W3031367701A5072862438 @default.
- W3031367701 hasAuthorship W3031367701A5076064890 @default.
- W3031367701 hasAuthorship W3031367701A5076832426 @default.
- W3031367701 hasAuthorship W3031367701A5088178599 @default.
- W3031367701 hasConcept C121608353 @default.
- W3031367701 hasConcept C126322002 @default.
- W3031367701 hasConcept C143998085 @default.
- W3031367701 hasConcept C188816634 @default.
- W3031367701 hasConcept C2776694085 @default.
- W3031367701 hasConcept C2777701055 @default.
- W3031367701 hasConcept C2778164965 @default.
- W3031367701 hasConcept C2779013556 @default.
- W3031367701 hasConcept C2779984678 @default.
- W3031367701 hasConcept C2780057760 @default.
- W3031367701 hasConcept C2780387249 @default.
- W3031367701 hasConcept C2780739268 @default.
- W3031367701 hasConcept C2989005 @default.
- W3031367701 hasConcept C31760486 @default.
- W3031367701 hasConcept C509974204 @default.
- W3031367701 hasConcept C535046627 @default.
- W3031367701 hasConcept C61943457 @default.
- W3031367701 hasConcept C71924100 @default.
- W3031367701 hasConceptScore W3031367701C121608353 @default.
- W3031367701 hasConceptScore W3031367701C126322002 @default.
- W3031367701 hasConceptScore W3031367701C143998085 @default.
- W3031367701 hasConceptScore W3031367701C188816634 @default.
- W3031367701 hasConceptScore W3031367701C2776694085 @default.
- W3031367701 hasConceptScore W3031367701C2777701055 @default.
- W3031367701 hasConceptScore W3031367701C2778164965 @default.
- W3031367701 hasConceptScore W3031367701C2779013556 @default.
- W3031367701 hasConceptScore W3031367701C2779984678 @default.
- W3031367701 hasConceptScore W3031367701C2780057760 @default.
- W3031367701 hasConceptScore W3031367701C2780387249 @default.
- W3031367701 hasConceptScore W3031367701C2780739268 @default.
- W3031367701 hasConceptScore W3031367701C2989005 @default.
- W3031367701 hasConceptScore W3031367701C31760486 @default.
- W3031367701 hasConceptScore W3031367701C509974204 @default.
- W3031367701 hasConceptScore W3031367701C535046627 @default.
- W3031367701 hasConceptScore W3031367701C61943457 @default.
- W3031367701 hasConceptScore W3031367701C71924100 @default.
- W3031367701 hasIssue "15_suppl" @default.
- W3031367701 hasLocation W30313677011 @default.
- W3031367701 hasOpenAccess W3031367701 @default.
- W3031367701 hasPrimaryLocation W30313677011 @default.
- W3031367701 hasRelatedWork W2794733391 @default.
- W3031367701 hasRelatedWork W2799275431 @default.
- W3031367701 hasRelatedWork W2970695644 @default.
- W3031367701 hasRelatedWork W3031367701 @default.
- W3031367701 hasRelatedWork W3088997525 @default.
- W3031367701 hasRelatedWork W3165566354 @default.
- W3031367701 hasRelatedWork W3207251837 @default.
- W3031367701 hasRelatedWork W4213038919 @default.
- W3031367701 hasRelatedWork W4244099730 @default.
- W3031367701 hasRelatedWork W4304690509 @default.
- W3031367701 hasVolume "38" @default.
- W3031367701 isParatext "false" @default.
- W3031367701 isRetracted "false" @default.
- W3031367701 magId "3031367701" @default.
- W3031367701 workType "article" @default.